系统性红斑狼疮的细胞因子疗法研究进展

被引：11
|
作者：
何阳阳
阎雨
杜冠华
机构：
[1] 中国医学科学院北京协和医学院药物研究所药物靶点研究和新药筛选北京市重点实验室
来源：
中国药理学与毒理学杂志 | 2013年 / 27卷 / 05期
关键词：
细胞因子; 系统性红斑狼疮; 细胞因子疗法; 自身免疫性疾病;
D O I：
暂无
中图分类号：
R593.241 [];
学科分类号：
摘要：
系统性红斑狼疮是困扰着人类健康的一种自身免疫性疾病,通常发生在免疫系统自身耐受性崩溃之后,免疫系统中大量的炎症介质如细胞因子参与了该病的进程,细胞因子疗法有望成为治疗系统性红斑狼疮的新的治疗手段。本综述以细胞因子作为切入点,阐述了与系统性红斑狼疮病理进程密切相关的细胞因子的作用,以及针对该疾病的细胞因子疗法的研究进展,认为以疾病不同时期的不同细胞因子的表达水平划分疾病的活性指数,根据活性指数选择不同的细胞因子抑制剂进行个性化的治疗,或许能够取得更好的疗效。
引用
收藏
页码：876 / 880
页数：5
相关论文
共 20 条
  • [1] Anti-interferon alpha treatment in SLE[J] . Kyriakos A. Kirou,Elena Gkrouzman.Clinical Immunology . 2013
  • [2] Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo‐controlled, double‐blind, dose‐escalation study[J] . Jacqueline M. McBride,Jenny Jiang,Alexander R. Abbas,Alyssa Morimoto,Jing Li,Romeo Maciuca,Michael Townsend,Daniel J. Wallace,William P. Kennedy,Jorn Drappa.Arthritis & Rheumatism . 2012 (11)
  • [3] Role of Treg Cells and TGF-β1 in Patients with Systemic Lupus Erythematosus: A Possible Relation with Lupus Nephritis[J] . Qian Xing,Houheng Su,Jiajia Cui,Bin Wang.Immunological Investigations . 2012 (1)
  • [4] Destruction of Salivary and Lacrimal Glands by Th1-Polarized Reaction in a Model of Secondary Sj?gren’s Syndrome in Lupus-Prone Female NZB?×?NZWF1 Mice[J] . Toshiharu Hayashi,Natsumi Shimoyama,Takuya Mizuno.Inflammation . 2012 (2)
  • [5] Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus[J] . Lesley J. Scott,Celeste B. Burness,Paul L. McCormack.BioDrugs . 2012 (3)
  • [6] Lupus: Novel therapies in clinical development[J] . Preeta Kaur Chugh.European Journal of Internal Medicine . 2011 (3)
  • [7] Therapeutic blockade of TNF in patients with SLE—Promising or crazy?[J] . Martin Aringer,Josef S. Smolen.Autoimmunity Reviews . 2011 (5)
  • [8] Current and novel therapeutics in the treatment of systemic lupus erythematosus
    Yildirim-Toruner, Cagri
    Diamond, Betty
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : 303 - 312
  • [9] Tumor Necrosis Factor-α Antagonist Etanercept Decreases Blood Pressure and Protects the Kidney in a Mouse Model of Systemic Lupus Erythematosus
    Venegas-Pont, Marcia
    Manigrasso, Michaele B.
    Grifoni, Samira C.
    LaMarca, Babbette B.
    Maric, Christine
    Racusen, Lorraine C.
    Glover, Porter H.
    Jones, Allison V.
    Drummond, Heather A.
    Ryan, Michael J.
    [J]. HYPERTENSION, 2010, 56 (04) : 643 - 649
  • [10] Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study[J] . Gabor G.Illei,YukoShirota,Cheryl H.Yarboro,JimmyDaruwalla,EdwardTackey,KazukiTakada,ThomasFleisher,James E.Balow,Peter E.Lipsky.Arthritis & Rheumatism . 2010 (2)
12